Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 10/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10270524 | 0.91 | GAA (0.48) | CTSLCTSKCTSSFPR2GAA | |
| SCHEMBL10270703 | 0.90 | GAA (0.46) | CTSLCTSKCTSSFPR2GAA | |
| SCHEMBL10270246 | 0.89 | GAA (0.46) | CTSLCTSKCTSSGAARECQL | |
| SCHEMBL10270426 | 0.87 | CTSS (0.50) | CTSLCTSKCTSSFPR2HDAC8 | |
| SCHEMBL10270430 | 0.85 | CTSL (0.65) | CTSLCTSKCTSS | |
| SCHEMBL9943827 | 0.85 | CTSL (0.57) | CTSLCTSKCTSS | |
| SCHEMBL9100213 | 0.85 | CTSL (0.57) | CTSLCTSKCTSS | |
| SCHEMBL9100192 | 0.85 | CTSL (0.57) | CTSLCTSKCTSS | |
| SCHEMBL10270264 | 0.84 | KLK7 (0.41) | CTSLCTSKCTSSFPR2GAA | |
| SCHEMBL9103806 | 0.84 | METAP2 (0.49) | CTSLCTSKCTSSFPR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | CTSE, CTSB, CTSS | CTSL 13/4885CTSK 8/4885CTSS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.